论文部分内容阅读
自1998年,我国证券市场上流行起“生物制药”概念以来,数十家上市公司通过投资控股、合资参股、购买产品生产经营权投资生物制药业。一些绩差股也把资产重组的重点放在了进军生物制药业上。一时间,不少具有“生物制药”概念的股票股价节节上升,市场反应十分热烈。鞍山合成(600669)由于兼具“资产重组”和“生物制药”两大概念以全年3.5%的升幅列深沪市场第二位。美国证券市场上,生物制药公司的股票也是十分热门的抢手货。“生物制药”概念能否成为证券市场上永远的话题呢?
Since 1998, the concept of “biopharmaceuticals” has been popular in China’s securities market. Dozens of listed companies have invested in the biopharmaceutical industry through investment holding, joint venture participation, and purchase of product production and management rights. Some performance stocks have also focused their asset restructuring efforts on entering the biopharmaceutical industry. For a time, many stocks with the concept of “biopharmaceuticals” have risen steadily, and the market has responded with enthusiasm. Anshan Synthetic (600669) ranked second in the Shenzhen and Shanghai markets due to the two major concepts of “asset reorganization” and “biologic pharmaceuticals” with a 3.5% annual increase. In the US stock market, the stocks of biopharmaceutical companies are also hot sellers. Can the concept of “biopharmaceuticals” become an eternal topic in the securities market?